Lee's Pharmaceutical Holdings Limited (0950) AI Stock Analysis

• Market Cap: HK$718.38M
• Dividend Yield: 2.25%
• Average Volume (3M): 376.53K
• Price to Earnings (P/E): 7.7
• Beta (1Y): 0.53
• Revenue Growth: 32.95%
• EPS Growth: 456.69%
• Country: HK
• Employees: 1,022
• Sector: Healthcare
• Sector Strength: 57
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.05
• Shares Outstanding: 588,835,300
• 10 Day Avg. Volume: 130,250
• 30 Day Avg. Volume: 376,533
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.68
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The overall score reflects strong revenue growth and a stable balance sheet with low leverage, countered by challenges in cash flow and profitability. The technical indicators suggest neutral momentum, while a low P/E ratio and decent dividend yield enhance the stock's attractiveness. The absence of earnings call and corporate events data means these areas could not be evaluated.

Lee's Pharmaceutical Holdings Limited Business Overview & Revenue Model

Company Description

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.

How the Company Makes Money

Lee's Pharmaceutical Holdings Limited generates revenue primarily through the sale of its proprietary and generic pharmaceutical products across various therapeutic areas. The company benefits from a diverse product portfolio that includes both branded and generic drugs, allowing it to capture different segments of the market. In addition to direct sales, Lee's Pharmaceutical engages in strategic partnerships and collaborations with other pharmaceutical companies for the co-development and co-marketing of drugs, further enhancing its revenue streams. The company's investment in research and development also plays a crucial role in sustaining long-term profitability by continuously introducing innovative products to the market.

Lee's Pharmaceutical Holdings Limited Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.05B	1.23B	1.27B	1.22B	1.22B
	Gross Profit
551.31M	770.75M	806.28M	781.07M	798.26M
	EBIT
36.04M	123.02M	-694.00K	151.92M	244.60M
	EBITDA
193.05M	229.06M	2.13B	279.43M	235.55M
	Net Income Common Stockholders
16.70M	51.28M	1.99B	78.53M	63.34M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
171.00M	189.30M	277.53M	414.54M	775.13M
	Total Assets
2.89B	2.78B	3.64B	3.25B	3.64B
	Total Debt
204.14M	163.49M	267.14M	156.71M	167.94M
	Net Debt
33.14M	-25.81M	-10.39M	-257.83M	-607.19M
	Total Liabilities
930.07M	939.50M	1.25B	1.14B	1.16B
	Stockholders Equity
2.04B	1.92B	2.46B	2.15B	2.30B
Cash Flow		Free Cash Flow
-45.89M	69.81M	-160.04M	-139.23M	39.38M
	Operating Cash Flow
110.08M	283.63M	210.68M	218.91M	399.95M
	Investing Cash Flow
-145.22M	-256.05M	-370.28M	-523.74M	-261.41M
	Financing Cash Flow
13.44M	-128.60M	60.97M	-9.80M	323.79M

Lee's Pharmaceutical Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0950, the sentiment is Positive. The current price of 1.36 is above the 20-day moving average (MA) of 1.32, above the 50-day MA of 1.33, and above the 200-day MA of 1.26, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.88 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0950.

Lee's Pharmaceutical Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1558	66 Neutral	HK$11.03B	21.11	5.88%	―	-42.02%	-76.29%
0950	58 Neutral	HK$718.38M	7.72	5.04%	2.25%	32.95%	456.69%
Sector *	52 Neutral	$5.35B	3.96	-42.60%	2.86%	17.58%	1.27%

Lee's Pharmaceutical Holdings Limited Corporate Events

Lee’s Pharmaceutical Announces AGM and Strategic Resolutions

Lee’s Pharmaceutical Holdings Limited has announced its upcoming Annual General Meeting (AGM) scheduled for May 22, 2025, where shareholders will consider several key resolutions. These include the approval of audited financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks authorization to repurchase up to 10% of its issued shares, reflecting a strategic move to manage its share capital and potentially enhance shareholder value.

Lee’s Pharmaceutical Declares Final Dividend for 2024

Lee’s Pharmaceutical Holdings Limited announced a final cash dividend of HKD 0.025 per share for the financial year ending December 31, 2024. The dividend reflects the company’s financial performance and commitment to providing returns to its shareholders, with the payment date set for June 16, 2025.

Lee’s Pharmaceutical Reports Robust Financial Growth in 2024

Lee’s Pharmaceutical Holdings Limited announced a substantial financial performance improvement for the year ended December 31, 2024. The company reported a 32.9% increase in revenue and a 457.5% rise in profit attributable to owners compared to the previous year. This significant growth is reflected in the earnings per share, which also saw a dramatic increase. The Board has recommended a final dividend of HK2.5 cents per share, highlighting confidence in the company’s financial health and future prospects.

Lee’s Pharmaceutical Projects Significant Profit Increase for 2024

Lee’s Pharmaceutical Holdings Limited has issued a positive profit alert, anticipating a significant increase in net profit for the year ending December 31, 2024, with expected figures between HK$83 million and HK$106 million, compared to HK$17 million the previous year. This improvement is attributed to robust sales growth from key products, decreased R&D expenses through portfolio optimization, and cost savings from management initiatives, despite challenges such as land use rights provisions and R&D impairment losses.

Lee’s Pharmaceutical Schedules Board Meeting to Approve Annual Results

Lee’s Pharmaceutical Holdings Limited has announced a board meeting scheduled for March 27, 2025, to discuss the approval of the company’s annual results for the year ending December 31, 2024, and to consider recommending a final dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential returns for investors.